STAR Market Healthcare ETF Huaxia turnover exceeds 40 million yuan, institutions bullish on innovative drug rebound

Industry
โดย Jiemian·Read original
Summary · why it matters

STAR Market Healthcare ETF Huaxia turnover exceeded 40 million yuan, with net capital inflows totaling 82.4338 million yuan over the past seven consecutive trading days. As of 2:14 p.m. on July 7, the ETF's intraday turnover rate reached 20.95%, with turnover of 40.0765 million yuan and the latest quote at 1.03 yuan. Zhongtai Securities believes that the pharmaceutical sector, especially innovative drugs, will be the first area to attract capital inflows, and is bullish on the rebound opportunity for innovative drugs. On the news front, a large number of A-share biomedical listed companies have issued significant positive profit forecasts in their semi-annual reports, and the total value of overseas licensing deals for domestic innovative drugs in the first quarter of 2026 has exceeded 60 billion US dollars. STAR Market Healthcare ETF Huaxia closely tracks the Shanghai Stock Exchange STAR Market Biomedical Index, which selects 50 securities of listed companies with larger market capitalizations in the biomedical and related fields on the STAR Market as constituents.

Impact on stocks 2

© 2026 MarketDXNews